<DOC>
	<DOCNO>NCT00492843</DOCNO>
	<brief_summary>The objective trial ass efficacy safety load dos versus standard dose intravenous Bondronat reduce pain patient lung cancer bone metastatic disease .</brief_summary>
	<brief_title>Loading Dose Standard Dose Intravenous Ibandronate Treating Patients With Lung Cancer Skeletal Metastasis</brief_title>
	<detailed_description>Patients lung cancer bone metastatic disease may experience moderate severe bone pain . Some research report loading dos Bondronat ( 6mg Bondronat three consecutive day ) great efficacy reduce pain patient malignant bone disease without unacceptable toxicity . So , design clinical trial compare efficacy safety profile load dos Bondronat standard dose Bondronat.Enrolled patient receive intravenous infusion either 6mg Bondronat three consecutive day 6mg Bondronat one day . The targeted sample size 120 individual . Primary outcome measure bone pain response ( ≥ 25 % decrease mean pain score maximum 15 % increase mean analgesic consumption ) . Secondary outcome measure efficacy include ECOG Performance status , analgesic consumption , bone marker , safety profile include AE laboratory parameter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written inform consent Age ≥ 18 year Histological cytological evidence lung cancer Presence bone metastasis document bone Xray , bone ECT , CT scan MRI scan Mean pain score ≥ 4 3day baseline period WORSE pain scale VAS Patients must stable dose analgesic 3day baseline period ( maximum 15 % variation allow ) ECOG Performance status 03 ( patient PS 3 must score base bone pain , underlie neoplastic disease ) Adequate renal function : creatinine clearance ≥ 50 ml/min ( cockroft formula ) serum creatinine ≤ 2.0mg/dl ( 168 µmol/L ) ; ALT AST within 2 time upper limit normal range Patients uncontrolled infection Hypocalcemia Patients receive bisphosphonate within 3 week start Baseline period currently receive another bisphosphonate Patients know hypersensitivity component ibandronic acid Patients pregnant lactate Radiotherapy bone within 28 day prior inclusion trial duration Patient currently treat investigational therapy receive within 30 day first schedule day dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ibandronate , Lung cancer , bone metastasis</keyword>
</DOC>